

Learn How to Improve Your HEDIS¹ Rates for Osteoporosis Management

Use this tip sheet to review key details of the Osteoporosis Management in Women Who Had a Fracture (OMW) measure, best practices and resources.

<p>Measure</p>	<p>Women ages 67–85 who suffered a fracture and had either a bone mineral density (BMD) test or prescription for a drug to treat osteoporosis in the six months after the fracture.</p> <p>Appropriate testing or treatment for osteoporosis after the fracture defined by any of the following criteria:</p> <ul style="list-style-type: none"> • A BMD test within six months/180 days of the fracture, or • Osteoporosis therapy or a dispensed prescription to treat osteoporosis filled within six months/180 days of the fracture.
<p>Exclusions</p>	<p>Patients who meet the following criteria:</p> <ul style="list-style-type: none"> • Had BMD test within 24 months preceding the fracture. • Have a fracture of a finger, toe, face or skull. • Received osteoporosis therapy within the 12 months preceding the fracture. • Received a dispensed prescription or had an active prescription to treat osteoporosis within the 12 months preceding the fracture. • Had another fracture within 60 days preceding the fracture. • Enrolled in an institutional Special Needs Plan (I-SNP) or living long-term in an institution from July 1 of the prior year through the end of the measurement year. • Have advanced illness and frailty from July 1 of the prior year through the end of the measurement year. • In palliative care. • In hospice.
<p>Best practices</p>	<ul style="list-style-type: none"> • Ask patients whether they have had falls or fractures since the last appointment. Address disparities in osteoporosis screening and management in diverse patient populations. • Evaluate women for risk factors that would increase the risk of osteoporosis. Some risk factors include low body weight, excessive alcohol intake, current tobacco use, history of fractures and use of certain medications. • Refer patients to case management for resources and help with post-fracture. • Set up a BMD screening process to identify patients with fractures: <ul style="list-style-type: none"> – Provide a BMD prescription and urge patients to complete the screening soon. – Make sure the screening site notifies you with results in a timely manner. – Set up a follow-up visit to discuss the results at the patient’s next visit. • Prescribe medication to treat osteoporosis. • Discuss osteoporosis prevention with your patients, such as taking calcium and vitamin D supplements, and taking part in weight-bearing exercises. • Promote evidence-based interventions, such as Fracture Liaison Services (FLS), coordinator-based, secondary fracture prevention services for the systemic identification and treatment of osteoporotic patients.



Often called a silent disease, osteoporosis reduces bone mass through structural deterioration, resulting in compromised bone strength. Osteoporosis is more common in women than in men. One in two women will have an osteoporosis-related fracture in their lifetime.²

(continued)

¹HEDIS®: Healthcare Effectiveness Data and Information Set

²National Osteoporosis Foundation at

www.nof.org/patients/what-is-osteoporosis: What is Osteoporosis and What Causes It.

Codes	Use the appropriate service codes when billing for OMW screenings	
	CPT Copyright 2017 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.	
	Bone mineral density tests	CPT code 76977, 77078, 77080-77081, 77085, 77086 ICD-10-PCS BP48ZZ1, BP49ZZ1, BP4GZZ1, BP4HZZ1, BP4LZZ1, BP4MZZ1, BP4NZZ1, BP4PZZ1, BQ00ZZ1, BQ01ZZ1, BQ03ZZ1, BQ04ZZ1, BRO0ZZ1, BR07ZZ1, BR09ZZ1, BROGZZ1
Osteoporosis therapy	HCPCS JO897, J1740, J3110, J3111, J3489	

Medications	Prescribe the appropriate medications for OMW	
	Description	Medication³
	Bisphosphonates	<ul style="list-style-type: none"> • Alendronate • Alendronate-cholecalciferol • Ibandronate • Risedronate • Zoledronic acid
Other agents	<ul style="list-style-type: none"> • Abaloparatide • Denosumab • Raloxifene • Romosozumab • Teriparatide 	

³Not all medications listed are on the 2022 Health Net Drug Formulary. Refer to mmp.healthnetcalifornia.com/prescription-drug-part-d/formulary.html.

Resources

- Final Recommendation Statement, Osteoporosis to Prevent Fractures: Screening. U.S. Preventive Services Task Force at www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosis-screening.
- National Committee for Quality Assurance (NCQA), HEDIS Measurement Year 2022, Volume 2: Technical Specifications for Health Plans, 2021.

*Health Net of California, Inc., Health Net Community Solutions, Inc. and Health Net Life Insurance Company are subsidiaries of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved.